A review of antipsychotics in the treatment of obsessive compulsive disorder

Ackerman D L , Greenland S (2002) Multivariate meta-analysis of controlled drug studies for obsessive compulsive disorder . J Clin Psychopharmacol 22: 309-317

Altschuler M (1962) Massive doses of trifluoperazine in the treatment of compulsive rituals . Am J Psychiat 119: 367-368

Atmaca M , Kuloglu M , Tezcan E , Gecici O (2002) Quetiapine augmentation in patients with treatment-resistant obsessive compulsive disorder. A single blind, placebo-controlled study . Int Clin Psychopharmacol 17: 115-119

Barr L C , Goodman W K , Anand A , McDougle C J , Price L H (1997) Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder . Am J Psychiat 154: 1293-1295

Barr L C , Goodman W K , McDougle C J , Delgado P L , Heninger G R , Charney D S , Price L H (1994) Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors . Arch Gen Psychiat 51: 309-317

Bejerot S , Bodlund O (1998) Response to high doses of citalopram in treatment-resistant obsessive compulsive disorder . Acta Psychopharmacol Scandinavia 98: 423-424

Blier P , Bergeron R (1996) Sequential administration of augmentation strategies in treatment resistant obsessive compulsive disorder: preliminary findings . Int Clin Psychopharmacol 11: 37-44

Bogan A M , Koran L M , Chuong H V , Vapnik T , Bystritsky A (2005) Quetiapine augmentation in obsessive compulsive disorder resistant to serotonin reuptake inhibitors: an open label study . J Clin Psychiat 66: 73-79

Bogetto F , Bellino S , Vaschetto P , Ziero S (2000) Olanzapine augmentation of fluvoxamine-refractory obsessive compulsive disorder (OCD): a twelve-week open trial . Psychiat Res 95: 91-98

Buchsbaum M S , Hollander E , Pallanti S , Baldini-Rossi N , Platholi J , Bloom R , Sood E (2002) Risperidone in Refractory OCD: Positron Emission Tomography Imaging . 42nd NCDEU Meeting, Boca Raton

Bymaster F P , Katner J S , Nelson D L , Hemrick-Luecke S K , Threlkeld P G , Heilingstein J H , Morin S M , Gehlert D R , Perry K W (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder . Neuropsychopharmacology 27(5): 699-711

Byerly M J , Goodman W K , Christenen R (1996) High doses of sertraline for treatment-resistant obsessive compulsive disorder . Am J Psychiat 153: 1232-1233

Bystritsky A , Ackerman D L , Rosen R , Vapnik T , Gorbis E , Maidment K M , Saxena S (2004) Augmentation of SSRI response in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial . J Clin Psychiat 65: 565-568

Carey P D , Vythilingum B , Seedat S , Muller J E , van Ameringen M , Stein D J (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study : BMC Psychiat 5(1): 5

Connor K M , Payne V M , Gadde K M , Zhang W Davidson J R (2005) The use of aripiprazole in obsessive compulsive disorder: preliminary observations in 8 patients . J Clin Psychiat 66(1): 49-51

Crocq M A , Leclercq P , Guillon M S , Bailey P E (2002) Open-label olanzapine in obsessive compulsive disorder refractory to antidepressant treatment . Eur Psychiat 17: 296-297

D’Amico G , Cedro C , Muscatello M R , Pandolfo G , Di Rosa A E , Zoccali R , La Torre D , D’Amigo C , Spina E (2003) Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder . Progress in Neuro-psychopharmacology and Biological Psychiat 27: 619-623

Dannon P N , Sasson Y , Hirschmann S , Iancu I , Grunhaus L J , Zohar J (2000) Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo-controlled trial . Eur Neuropsychopharmacol 10: 165-169

Denys D , de Geus F , van Megen H J G M , Westenberg H G M (2004a) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors . J Clin Psych 65: 1040-1048

Denys D , Klompmakers A A , Westenberg H G (2004c) Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine . Psychopharmacology (Berl) 176(2): 195-203

Denys D , van der Wee N , Janssen J , De Geus F , Westenberg H G (2004b) Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder . Biol Psychiat 55: 1041-1045

Denys D , van Megen H , Westenberg H (2002) Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder: an open label study . J Clin Psychiat 63: 700-703

Erzegovesi S , Guglielmo E , Siliprandi F , Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment for obsessive compulsive disorder: a double-blind placebo-controlled study . Eur Neuropsychopharmacol 15(1): 69-74

Fallon B A , Liebowitz M R , Campeas R , Schneier F R , Marshall R , Davies S , Goetz D , Klein D F (1998) Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study . Arch Gen Psychiat 55: 918-924

Fineberg N A , Sivakumaran T , Roberts A , Gale T (2005) Adding quetiapine to SRI in treatment-resistant obsessive compulsive disorder: a randomised controlled treatment study . Int Clin Psychopharmacol 20: 223-226

Francobandiera G (2001) Olanzapine augmentation of serotonin uptake inhibitors in obsessive compulsive disorder: an open study . Can J Psychiat 46: 356-358

Geller D A , Biederman J , Evelyn Stewart S , Mullin B , Martin A , Spencer T , Faraone S V (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in paediatric obsessive compulsive disorder . Am J Psychiat 160: 1919-1928

Grady T A , Pigott T A , L’Heureux F , Hill J L , Berntein S E , Murphy D L (1993) Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder . Am J Psychiat 150: 819-821

Hollander E , Rossi N B , Sood E , Pallanti S (2003a) Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo controlled study . Int J Neuropsychopharmacol 6: 397-401

Hollander E , Kaplan A , Stahl S M (2003b) A double-blind placebo-controlled trial of clonazepam in obsessive-compulsive disorder . World J Biological Psychiat 4: 30-34

Hussain M Z , Ahad A (1970) Treatment of obsessive compulsive neurosis . Can Med Assoc J 103: 648

Koran L M , Ringold A L , Elliott M A (2000) Olanzapine augmentation for treatment-resistant obsessive compulsive disorder . J Clin Psychiat 61: 514-517

Maina G , Albert U , Ziero S , Bogetto F (2003) Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: What if antipsychotic is discontinued? Int Clin Psychopharmacol 18: 23-28

March J S , Frances A , Kahn D A , Carpenter D (1997) The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder . J Clin Psychiat 58 (suppl.): 1-72

Marek G J , Carpenter L L , McDougle C J , Price L H (2003) Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders . Neuropsychopharmacol 28: 402-412

Mataix-Cols D , Rauch S , Manzo P A , Jenike M A , Baer L (1999) Use of factor-analysed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive compulsive disorder . Am J Psychiat 156: 1409-1416

McDougle C J , Barr L C , Goodman W K , Pelton G H , Aronson S C , Anand A , Price L H (1995b) Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder . Am J Psychiat 152: 423-429

McDougle C J , Epperson C N , Pelton G H , Wasylink S , Price L H (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder . Arch Gen Psychiat 57: 794-801

McDougle C J , Fleischmann R L , Epperson C N , Wayslink S , Leckmann J F , Price L H (1995a) Risperidone addition in fluvoxamine refractory obsessive compulsive disorder: three cases . J Clin Psychiat 56: 526-528

McDougle C J , Goodman W K , Leckman J F , Holzer J C , Barr L C , McCance-Katz E (1993) Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder . Am J Psychiat 150: 647-649

McDougle C J , Goodman W K , Leckman J F , Lee N C , Heninger G R , Price L H (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics . Arch Gen Psychiat 51: 302-308

McDougle C J , Goodman W K , Price L H , Delgado P L , Krystal J H , Charney D S , Heninger G R (1990) Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder . Am J Psychiat 147: 652-654

McDougle C J , Price L H , Goodman W K , Charney D S , Heninger G R (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy . J Clin Psychopharmacol 11: 175-184

McDougle C J , Walsh K H (2001) Treatment for refractory OCD. In: Fineberg N A , Marazitti D , Stein D (eds), Obsessive Compulsive Disorder: A Practical Guide. Martin Dunitz, London

Metin O , Yaziki K , Tot S , Yazici A E (2003) Amisulpride augmentation in treatment-resistant obsessive compulsive disorder: an open trial . Hum Psychopharmacol 18: 463-467

Mohr N , Vythilingum B , Emsley R A , Stein D J (2002) Quetiapine augmentation of serotonin reuptake inhibitors in obsessive compulsive disorder . Int Clin Psychopharmacol 17: 37-40

Mundo E , Bareggi S R , Pirola R , Bellodi L (1999) Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable? Biol Psychiat 45: 290-294

Mundo E , Guglielmo E , Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine; a double-blind, placebo-controlled study . Int Clin Psychopharmacol 13: 219-224

O’Regan J B (1970) Treatment of obsessive-compulsive neurosis . Can Med Assoc J 103: 650-651

Pallanti S , Hollander E , Bienstock C , Koran L , Leckman J , Marazziti D , Pato M , Stein D , Zohar and the International Treatment-Refractory OCD Consortium (2002a) Treatment non-response in OCD: methodological issues and operational definitions . Int J Neuropsychopharmacol 5: 181-191

Pallanti S , Quercioli L , Bruscoli M (2004) Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study . J Clin Psychiat 65(10): 1394-1399

Pallanti S , Quercioli L , Koran L M (2002b) Citalopram infusions in resistant obsessive compulsive disorder: an open trial . J Clin Psychiat 63: 796-801

Pallanti S , Quercioli L , Paiva R S , Koran L M (1999) Citalopram for treatment-resistant obsessive-compulsive disorder . Eur Psychiat 14: 101-106

Pfanner C , Marazziti D , Dell’Osso L , Presta S , Gemignani A , Milanfranchi A , Cassano G B (2000) Risperidone augmentation in refractory obsessive compulsive disorder: an open-label study . Int Clin Psychopharmacol 15: 297-301

Pigott T A , L’Heureux F , Hill J L , Bihari K , Bernstein S E , Murphy D L (1992a) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder . J Clin Psychopharmacol 12: 11-18

Pigott T A , L’Heureux F , Rubinstein C F , Hill J L , Murphy D L (1992b) A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine . New Research Abstracts NR 144 presented at the 145th Annual Meeting of the American Psychiatric Association, Washington, DC, USA

Pigott T A , Pato M T , L’Heureux F , Hill J L , Grover G N , Bernstein S E , Murphy D L (1991) A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder . J Clin Psychopharmacol 11: 242-248

Poyurovsky M , Koran L (2005) Obsessive compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications . J Psychiatr Res 39(4): 399-408

Rivers-Bulkeley N , Hollender M H (1982) Successful treatment of obsessive-compulsive disorder with loxapine . Am J Psychiat 139: 1345-1346

Sareen J , Kirshner A , Lander M , Kjeniested K D , Eleff M K , Reiss J P (2004) Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder? A systematic review . J Affective Disorders 82: 167-174

Saxena S , Brody A L , Ho M L , Zohrabi N , Maidment K M , Baxter L (2003) Differential brain metabolic predictors of response to paroxetine in obsessive compulsive disorder versus major depression . Am J Psychiat 160: 522-532

Saxena S , Wang D , Bystritsky A , Baxter Jr L R (1996) Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder . J Clin Psychiat 57: 303-306

Sevincok L , Topuz A (2003) Lack of efficacy of low dose quetiapine addition in refractory obsessive compulsive disorder . J Clin Psychopharmacol 23: 448-450

Shapira N A , Ward H E , Mandoki M , Murphy T K , Yang M C , Blier P , Goodman W K (2004) A double-blind placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive compulsive disorder . Biol Psychiat 55: 553-563

Stein D J , Bouwer C , Hawkridge S , Emsley R A (1997) Risperidone augmentation of serotonin reuptake inhibitors in obsessive compulsive and related disorders . J Clin Psychiat 58: 119-122

Stein D , Montgomery S A , Kasper S , Tanghoj P (2001) Predictors of response to pharmacotherapy with citalopram in obsessive compulsive disorder . Int Clin Psychopharmacol 16: 357-361

Szegedi A , Wetzel H , Leal M , Hartter S , Hiemke C (1996) Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data . J Clin Psychiat 57: 257-264

Trethowan W H , Scott P A (1955) Chlorpromazine in obsessive-compulsive and allied disorders . Lancet 268: 781-785

Weiss E L , Potenza M N , McDougle C J , Epperson C N (1999) Olanzapine addition in obsessive compulsive disorder refractory to selective serotonin reuptake inhibitors; an open-label case series . J Clin Psychiat 60: 524-527